Skip to content

Trial · Interventional

CompletedPhase 2Registry data

Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

NCTNCT00154414 (opens ClinicalTrials.gov in a new tab)Other idNN2211-1334Other idJapicCTI-050131
Open at ClinicalTrials.govAsk about this trial

Overview

Status
Completed
Phase
Phase 2
Enrollment
226 participants (actual)
Sponsor
Novo Nordisk A/S · Industry
Design
Randomized · Double masking
Countries
1 country

Japan

Start
Jan 2005
Primary completion
May 2006
Completion
May 2006
First posted
12 Sept 2005 (estimated)
Last update posted
25 Jan 2017 (estimated)
Conditions
Diabetes · Diabetes Mellitus, Type 2

Timeline

1 trial · 1 completed

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
200520062007
  1. Ph 2

    Effect of Liraglutide on Blood Glucose Control in Japanese Subjects With Type 2 Diabetes

    NCT00154414

    Jan 2005 to May 2006

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

This trial is conducted in Japan. The aim of this research trial is to evaluate the effect of treatment with liraglutide or placebo on blood glucose control after 14 weeks in Japanese subjects with type 2 diabetes. Liraglutide or placebo is administered by injection once daily in the evening. The trial is a multi-national trial with treatment concealed to participating subjects, investigators and the sponsor. Treatment allocation is random with equal chance of being assigned to each group.

Interventions

  • liraglutideDrug

Arms0

The registry lists no arms for this trial.

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. HbA1c

    Time frame · after 14 weeks treatment

Secondary outcomes(3)

  1. Glycaemic control parameters (fasting plasma glucose, post prandial plasma glucose) after 14-week treatment

  2. Body weight after 14 weeks.

  3. Safety and tolerability

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

Completed trials do not always post results.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies2

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2008

13 results

Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: A double-blind, randomized, controlled trial in Japanese patients with type 2 diabetes.

Seino et al. 2008Diabetes research and clinical practicecited by 89

PMID 18495285DOI 10.1016/j.diabres.2008.03.018PUB-18495285

Full text at the publisher13 results
Publisher pageSee results (13)

More studies

1 study on this page

Indexing hint: Meta-analysis (pooled) · 2015

Corrected

Is there a link between liraglutide and pancreatitis? A post hoc review of pooled and patient-level data from completed liraglutide type 2 diabetes clinical trials.

Jensen et al. 2015Diabetes carecited by 45

PMID 25504028DOI 10.2337/dc13-1210PUB-25504028

Rights unknown
Source linkRead the notice

Eligibility

Who could join, as posted.

Sex
All
Age
from 20 Years up to 74 Years
Healthy volunteers
Not accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * Subjects diagnosed with type 2 diabetes and treated with diet therapy with or without single oral drug therapy * 7.0 % =\< HbA1c \< 10.0 % * Body Mass Index (BMI) \< 30.0 kg/m\^2 Exclusion Criteria: * Subjects treated with thiazolidinediones or insulin * Subjects with any serious medical conditions

PepBank is a research reference. Talk to a doctor before you use any peptide.